EFFICACY AND SAFETY OF RADOTINIB IN CHRONIC PHASE CHRONIC MYELOID LEUKEMIA PATIENTS WITH RESISTANCE OR INTOLERANCE TO BCR-ABL1 TYROSINE KINASE INHIBITORS

Radotinib (IY5511HCL), a novel and selective BCR-ABL1 tyrosine kinase inhibitor, has shown pre-clinical and phase I activity and safety in chronic myeloid leukemia.This phase II study investigated the efficacy and safety of radotinib in Philadelphia chromosome-positive chronic phase-chronic myeloid leukemia patients with resistance and/or intoleran

Introduction: Chronic kidney disease (CKD) is described by structural or functional defects staying for three months.End-stage kidney disease (ESKD) patients undergoing renal replacement therapy the lazy susan ramen (RRT) face complications and increased susceptibility to infections due to their compromised immune system.In addition, malnutrition a

Declaration of smallpox eradication by the WHO in 1980 led to discontinuation of the worldwide vaccination campaign.The increasing percentage of unvaccinated individuals, the existence of its causative infectious agent variola virus plastic molcajete bowls (VARV), and the recent synthetic achievements increase the threat of intentional or accidenta